It was approved via accelerated drug approval by the US Food and Drug Administration in 2011, based on the findings of two early phase clinical trials demonstrating prolonged progression-free survival (PFS; 6–10 months) and high response rates (50–57%) in patients with ALK-positive NSCLC[13, 14]. This evidence concerns the gene ALK and non-small cell lung carcinoma.